Cytek Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cytek Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $54 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $56 tied up three years earlier. More money tied up than 95% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 23% in 3 years, but profit fell: $185 less profit per $100 of extra sales. Lower than 90% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
2.0×Over the last 3 years its own operating cash covered its investment spending (capex) 2.0 times.
Higher than 74% of Healthcare companies in United States.
Cash Locked Ratio
$54For every $100 of sales, $54 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $56 tied up three years earlier.
More money tied up than 95% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$185Sales grew 23% in 3 years, but profit fell: $185 less profit per $100 of extra sales.
Lower than 90% of Healthcare companies in United States.
Asset Productivity Ratio
+23% / -11%In 3 years sales changed by +23% while total assets changed by -11%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-0.7×Operating cash was negative last year, while some debt falls due within a year.
Higher than 67% of Healthcare companies in United States.
Cash Cushion Ratio
+34%Cash, after subtracting all debt, equals 34% of its market value (net cash).
Higher than 70% of Healthcare companies in United States.
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 66% of Healthcare companies in United States.
Tangible Net Worth Ratio
90%Of every $100 of net worth, $90 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 72% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Cytek Biosciences, Inc. made a loss over the last year. Cytek Biosciences, Inc. owes $0.28 for every $1 it owns. Cytek Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCytek Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.19The share price is 2.19 times Cytek Biosciences, Inc.'s book value per share, lower than 55% of Healthcare companies in United States.
Market cap
$706 MThe total market value of all of Cytek Biosciences, Inc.'s shares at today's price (share price × number of shares), larger than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$322 MWhat Cytek Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.48Net worth divided by the number of shares. The share price of $5.43 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-23.0%Cytek Biosciences, Inc. lost 23.0% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
Owes vs Owns
0.28×Cytek Biosciences, Inc. owes $0.28 for every $1 it owns (low), lower than 62% of Healthcare companies in United States.
Dividend yield
NoneCytek Biosciences, Inc. does not currently pay a dividend.
Revenue growth
+1%Revenue rose 1% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Profit growth
LossCytek Biosciences, Inc. made a loss in each of the last two years.
Profit margin
-33.0%Cytek Biosciences, Inc. lost $33 for every $100 of revenue.
Interest cover
Not coveredCytek Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCytek Biosciences, Inc. held $238 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cytek Biosciences, Inc.: $706 M ÷ $322 M (30 Jun 2026) = 2.2.
What is Cytek Biosciences, Inc.'s return on equity?
Cytek Biosciences, Inc. lost 23.0% of its shareholders' money over the last year, higher than 65% of Healthcare companies in United States.
How much does Cytek Biosciences, Inc. owe compared with what it owns?
Cytek Biosciences, Inc. owes $0.28 for every $1 it owns (low), lower than 62% of Healthcare companies in United States.
Does Cytek Biosciences, Inc. pay a dividend?
No. Cytek Biosciences, Inc. does not currently pay a dividend.
Is Cytek Biosciences, Inc.'s revenue growing?
Revenue rose 1% in the year to Dec 2025, and grew 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.